At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Domperidone Dose and the Risk of Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease: A Population-Based Cohort Study Research Protocol
In Brief
An observational study evaluating Domperidone (drug) for Chronic Kidney Disease (CKD). Completed, enrolled 15,000 participants across 1 site.
Detailed Summary
This study will assess whether initiating domperidone at doses ≥30 mg/day compared to \<30 mg/day in patients with advanced chronic kidney disease (CKD) (estimated glomerular filtration rate \[eGFR\] \<45 mL/min/1.73 m² but not receiving dialysis) is associated with a higher 30-day risk of a composite outcome of all-cause hospitalization or all-cause emergency visits or all-cause mortality.
Study Details
Timeline
Interventions
The primary exposure of interest will be oral domperidone at a dose of 30 mg or more per day, which represents the median dose found in high-throughput computing analyses. For the primary comparison, oral domperidone at doses below 30 mg per day will be chosen to reduce the influence of indication bias.